Emilia Prakoso1, Warwick S Selby. 1. AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Department of Medicine, University of Sydney, Australia.
Abstract
BACKGROUND: Although small bowel (SB) involvement is found at postmortem in 50-60% of melanoma patients, diagnosis is only made during life in 10% of cases. This study reports the findings of capsule endoscopy (CE) in melanoma patients referred for investigation of suspected SB involvement. METHODS AND SUBJECTS: Eight men and five women with known or previous melanoma were referred for CE between December 2003 and September 2006. The indications were gastrointestinal bleeding (three), anemia (six), positive fecal occult blood test (one), abnormal imaging (two), and abdominal pain (one). RESULTS: CE showed SB metastases in five patients and excluded SB involvement in eight. All patients had previous investigations with either endoscopy, push enteroscopy, SB follow-through, CT scan, and/or PET scan. CE showed new lesions not detected by other investigation modalities. CE also ruled out SB metastases when other tests were nondiagnostic. All five patients with SB metastases detected underwent surgical resection. At follow-up after CE of a mean 8.4 months (1-23 months) and 4.9 months (0.25-10 months) after surgery, five patients had died, including three of those who had undergone resection of SB metastases. Seven patients were still alive, including two who had SB surgery. One patient was lost to follow-up. CONCLUSIONS: CE may detect the presence and extent of SB metastases in patients with melanoma more reliably than conventional investigations. It should be considered in the workup of melanoma patients with suspected SB disease.
BACKGROUND: Although small bowel (SB) involvement is found at postmortem in 50-60% of melanomapatients, diagnosis is only made during life in 10% of cases. This study reports the findings of capsule endoscopy (CE) in melanomapatients referred for investigation of suspected SB involvement. METHODS AND SUBJECTS: Eight men and five women with known or previous melanoma were referred for CE between December 2003 and September 2006. The indications were gastrointestinal bleeding (three), anemia (six), positive fecal occult blood test (one), abnormal imaging (two), and abdominal pain (one). RESULTS: CE showed SB metastases in five patients and excluded SB involvement in eight. All patients had previous investigations with either endoscopy, push enteroscopy, SB follow-through, CT scan, and/or PET scan. CE showed new lesions not detected by other investigation modalities. CE also ruled out SB metastases when other tests were nondiagnostic. All five patients with SB metastases detected underwent surgical resection. At follow-up after CE of a mean 8.4 months (1-23 months) and 4.9 months (0.25-10 months) after surgery, five patients had died, including three of those who had undergone resection of SB metastases. Seven patients were still alive, including two who had SB surgery. One patient was lost to follow-up. CONCLUSIONS: CE may detect the presence and extent of SB metastases in patients with melanoma more reliably than conventional investigations. It should be considered in the workup of melanomapatients with suspected SB disease.
Authors: Konstantinos Kouladouros; Daniel Gärtner; Steffen Münch; Mario Paul; Michael R Schön Journal: World J Gastroenterol Date: 2015-03-14 Impact factor: 5.742
Authors: Eduardo Redondo-Cerezo; Antonio Damián Sánchez-Capilla; Paloma De La Torre-Rubio; Javier De Teresa Journal: World J Gastroenterol Date: 2014-11-14 Impact factor: 5.742
Authors: Eva Mendes Serrao; Ana Maria Costa; Sergio Ferreira; Victoria McMorran; Emma Cargill; Caroline Hough; Ashley S Shaw; Brent O'Carrigan; Christine A Parkinson; Pippa G Corrie; Timothy J Sadler Journal: Insights Imaging Date: 2022-10-04
Authors: Eva Mendes Serrao; Emily Joslin; Victoria McMorran; Caroline Hough; Cheryl Palmer; Sarah McDonald; Emma Cargill; Ashley S Shaw; Brent O'Carrigan; Christine A Parkinson; Pippa G Corrie; Timothy J Sadler Journal: Cancer Imaging Date: 2022-06-14 Impact factor: 5.605
Authors: Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams Journal: Cochrane Database Syst Rev Date: 2019-07-01